Target TSH and Free T4 for Pregnant Patients with Hyperthyroidism
For pregnant women being treated for hyperthyroidism, maintain free T4 at or just above the upper limit of the normal (non-pregnant) reference range while keeping TSH in the low-normal range. 1
Treatment Targets
The Endocrine Society guideline provides the clearest framework for managing hyperthyroidism in pregnancy:
- Free T4 target: At or just above the upper limit of the non-pregnant reference range 1
- Alternative target: Total T4 at 1.5 times the upper limit of normal reference range 1
- TSH target: Low-normal range (suppressed but detectable) 1
The rationale for these targets is to minimize antithyroid drug exposure to the fetus while adequately treating maternal hyperthyroidism. Since antithyroid drugs cross the placenta, keeping maternal free T4 in the upper normal range prevents fetal hypothyroidism from overtreatment 1, 2.
Monitoring Strategy
- Initial monitoring: Check thyroid function every 2-4 weeks after initiating or adjusting antithyroid drug therapy 1
- Parameters to measure: TSH and free T4 are essential; approximately 73% of Asian clinicians use this combination 3
- Drug switching consideration: If switching from PTU to methimazole after first trimester, reassess thyroid function after 2 weeks, then every 2-4 weeks 1
Key Clinical Pitfalls
Avoid over-treatment: The most common error is using too much antithyroid medication, which can cause fetal hypothyroidism since these drugs cross the placenta more readily than maternal thyroid hormone 2, 4. The fetus depends on maternal T4 for brain development, particularly in the first half of pregnancy.
Use the lowest effective dose: Titrate antithyroid drugs to maintain free T4 in the upper normal range rather than normalizing TSH, as a suppressed TSH is acceptable and expected in treated Graves' disease during pregnancy 1, 5.
Third trimester adjustment: Antithyroid drug doses often can be reduced in the third trimester due to the immunosuppressive effects of pregnancy on Graves' disease 5.
Drug Selection Context
While not directly about targets, it's relevant that PTU is preferred in the first trimester (due to lower risk of congenital abnormalities), with consideration for switching to methimazole after the first trimester (due to PTU's rare but severe hepatotoxicity risk) 1.